肿瘤药学2025，Vol.15Issue(3)：309-321,13.DOI:10.3969/j.issn.2095-1264.2025.03.03
B细胞淋巴瘤药物治疗进展
Advances in pharmacotherapy for B-cell lymphoma
摘要
Abstract
In recent years,remarkable advances have been achieved in the pharmacological management of B-cell lym-phomas.In frontline therapy,novel immunochemotherapy-based combinations,including R-CHOP+X regimens,Bruton's tyrosine kinase(BTK)inhibitors,antibody-drug conjugates(ADCs),and bispecific antibodies,have significantly improved survival outcomes.For relapsed/refractory(R/R)B-cell lymphomas,bispecific antibodies,chimeric antigen receptor T-cell(CAR-T)therapies,and next-generation targeted agents(e.g.,BTK and BCL-2 inhibitors)have demonstrated potential for deep and durable responses.This review systematically summarizes the latest therapeutic progress stratified by frontline and R/R settings across major B-cell lymphoma subtypes:diffuse large B-cell lymphoma(DLBCL),follicular lymphoma(FL),mantle cell lymphoma(MCL),and chronic lymphocytic leukemia(CLL).Emphasis is placed on therapeutic break-throughs in targeted therapy,immunotherapy,and cellular therapy.关键词
B细胞淋巴瘤/CHOP/免疫治疗联合化疗/双特异性抗体/CAR-TKey words
B-cell lymphoma/CHOP/Immunochemotherapy/Bispecific antibodies/CAR-T分类
医药卫生引用本文复制引用
孙瑞阳,张清媛,赵曙..B细胞淋巴瘤药物治疗进展[J].肿瘤药学,2025,15(3):309-321,13.基金项目
哈尔滨医科大学肿瘤医院海燕基金(JJZD2022-10) （JJZD2022-10）
北京医学奖励基金会(YXJL-2020-0785-1072). （YXJL-2020-0785-1072）
